For the first quarter of 2026, analysts expect Natera to deliver consensus revenue of $522.5 million and an EPS of -$0.53, with the stock currently trading at $162.15 compared to a consensus price target of $192.00.
Investors are primarily focused on Signatera test volume growth, as this remains the critical engine for Natera’s high-margin oncology segment. The market is also looking for updates on the company's progress toward achieving sustainable cash flow break-even and any developments in ongoing patent litigation. Recent performance has been bolstered by expanded Medicare coverage for MRD testing, making volume execution and gross margin expansion the top priorities for this report.